INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tesaro, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
21 nov. 2018 12h47 HE
|
Schall Law
LOS ANGELES, Nov. 21, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tesaro, Inc. (“Tesaro” or...
TESARO Announces Second-Quarter 2018 Operating Results
02 août 2018 16h05 HE
|
TESARO, Inc.
ZEJULA® Q2 net sales totaled $54 million compared to $26 million for Q2 2017QUADRA sNDA submission planned for Q4 2018PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of...
TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer
05 juin 2018 08h30 HE
|
TESARO, Inc.
WALTHAM, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with...
TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
01 juin 2018 03h00 HE
|
TESARO, Inc.
Inclusion in the Cancer Drugs Fund will give more women in England and Wales with recurrent, platinum-sensitive ovarian cancer access to ZEJULA via a managed access arrangementZEJULA was launched in...
TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel
11 avr. 2018 08h30 HE
|
TESARO, Inc.
Agreement covers all indications for ZEJULA, excluding prostate cancer ZUG, Switzerland and PETACH TIKVA, Israel, April 11, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an...
TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany
15 déc. 2017 04h00 HE
|
TESARO, Inc.
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, without the need for BRCA testing and regardless of biomarker statusZEJULA is the only PARP inhibitor to...
TESARO Secures $500 Million Non-Dilutive Term Loan Financing
21 nov. 2017 08h00 HE
|
TESARO, Inc.
WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has entered into a definitive term loan agreement...
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
20 nov. 2017 07h00 HE
|
TESARO, Inc.
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker statusApproval supported by robust data from a randomized,...
TESARO Announces Third-Quarter 2017 Operating Results
07 nov. 2017 16h05 HE
|
TESARO, Inc.
ZEJULA® was the most prescribed PARP inhibitor in U.S. with Q3 net sales of $39.4 millionPositive CHMP opinion issued for ZEJULA in E.U.; commercial launch anticipated to begin by year-endExpansion of...
TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
25 oct. 2017 19h15 HE
|
TESARO, Inc.
VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administrationAvailability of new formulation offers healthcare providers the flexibility to choose oral or IV...